Reuters logo
8 months ago
BRIEF-AstraZeneca reports data from study on Tagrisso
December 9, 2016 / 1:17 PM / 8 months ago

BRIEF-AstraZeneca reports data from study on Tagrisso

Dec 9 (Reuters) -

* AstraZeneca says Tagrisso reduced risk of disease progression by 70 percent and improved progression-free survival by almost six months

* AstraZeneca says data showed Tagrisso offered a statistically-significant improvement in PFS versus standard platinum-based doublet chemotherapy

* Reports data from Aura3 Phase III trial on Tagrisso Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below